Articles tagged ‘dabigatran’

Dabigatran has the potential for serious adverse events, according to a safety warning issued recently by the Japanese Ministry of Health, Labour and Welfare after the deaths of five patients.

The superiority of dabigatran to warfarin, as reported by the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial, may be offset by its cost, according to an editorial¹ published recently in Circulation.

New guidelines[1] for managing atrial fibrillation (AF) have been jointly published by the American Heart Association (AHA), American College of Cardiology (ACC), and Heart Rhythm Society (HRS), containing some information which may not be as comprehensive as the recently released AF guidelines from the Canadian Cardiovascular Society (CCS) and the European Society of Cardiology (ESC) in September and October respectively.

The new European Society of Cardiology (ESC)guidelines for the management of atrial fibrillation (AF), have now included guidance on the role of a novel oral treatment, dabigatran etexilate, for the prevention of stroke and systemic embolism in patients with AF (1)

“Worldwide, strokes are the most common cause of death. This makes it a top priority for medicine to expand prevention in this area,” said Prof. Dr. Karl Max Einhäupl, from the University Clinic Charité in Berlin, who is co-chair of the Annual Meeting of the European Neurological Society (ENS) which took place in Berlin recently.

New sub-group analysis from the landmark RE-LY study has shown dabigatran etexilate significantly reduces the risk of stroke compared to warfarin irrespective of a patient’s risk profile for stroke.

A record number of 31,371 delegates attended the European Society of Cardiology (ESC)Congress in Barcelona this week. Clinical trials in atrial fibrillation were among the most well attended sessions, receiving worldwide news coverage within minutes of presentation. Principal among these were RE-LY and PLATO, details of which we feature here.